Targeted therapy has transformed the treatment of advanced breast cancer by improving outcomes with fewer systemic side effects. XILINGIO 25/5 mg Tablets are a combination therapy widely used in hormone receptor–positive, HER2-negative breast cancer. At Unnati Pharmax, we offer the reliable global export of XILINGIO 25/5 mg from India, ensuring quality, authenticity, and regulatory compliance.
This blog explains XILINGIO 25/5 uses, composition, mechanism of action, dosage, side effects, and export availability.
What is XILINGIO 25/5 mg?
XILINGIO 25/5 mg Tablets contain a fixed-dose combination of:
-
Palbociclib 25 mg
-
Letrozole 5 mg
This combination is designed to slow cancer cell growth by blocking cell cycle progression and reducing estrogen levels in the body.
Uses of XILINGIO 25/5 mg Tablets
XILINGIO 25/5 mg is commonly prescribed for:
-
Hormone receptor–positive (HR+), HER2-negative advanced breast cancer
-
Metastatic breast cancer in postmenopausal women
-
First-line endocrine-based therapy
-
Disease progression prevention
Therefore, XILINGIO 25/5 mg plays a crucial role in modern breast cancer management.
How Does XILINGIO 25/5 mg Work?
XILINGIO works through a dual mechanism:
-
Palbociclib inhibits CDK4/6 enzymes, stopping cancer cell division
-
Letrozole reduces estrogen production, slowing hormone-driven tumor growth
As a result, tumor progression is significantly delayed and treatment outcomes improve.
Dosage and Administration
-
Taken orally once daily
-
Usually administered in treatment cycles as prescribed
-
Can be taken with or without food
⚠️ Important: Dosage and treatment cycles must be strictly followed under oncologist supervision with regular blood monitoring.
Possible Side Effects
Some patients may experience:
-
Low white blood cell count (neutropenia)
-
Fatigue
-
Nausea
-
Hair thinning
-
Hot flashes
-
Joint or muscle pain
However, with proper monitoring, most side effects are manageable.
Precautions and Warnings
Patients should inform their doctor if they have:
-
Liver disorders
-
Active infections
-
Heart conditions
-
Pregnancy or breastfeeding plans
Regular blood counts and liver function tests are recommended during treatment.
Why Choose Unnati Pharmax for XILINGIO 25/5 Export?
Unnati Pharmax is a trusted Indian pharmaceutical exporter serving global oncology markets.
Our Key Strengths
-
WHO-GMP approved supply partners
-
Competitive international pricing
-
Export-grade, tamper-proof packaging
-
Complete regulatory documentation
-
Timely worldwide delivery
As a result, international buyers trust Unnati Pharmax for oncology medicines.
Global Export of XILINGIO 25/5 mg Tablets
We export XILINGIO 25/5 mg to:
-
Africa
-
Middle East
-
Southeast Asia
-
CIS countries
-
Latin America
Additionally, we provide full export documentation support for smooth customs clearance.
Frequently Asked Questions (FAQs)
1. What is XILINGIO 25/5 mg used for?
It is used to treat HR-positive, HER2-negative advanced or metastatic breast cancer.
2. Is XILINGIO 25/5 mg chemotherapy?
No. It is a targeted hormonal therapy, not chemotherapy.
3. Can XILINGIO 25/5 mg be exported from India?
Yes. Unnati Pharmax exports XILINGIO 25/5 mg with full regulatory compliance.
4. How should XILINGIO 25/5 mg be stored?
Store at room temperature, away from moisture and direct sunlight.
5. Why buy XILINGIO 25/5 mg from Unnati Pharmax?
Because we ensure authentic medicines, export expertise, and consistent global supply.
Conclusion
In summary, XILINGIO 25/5 mg Tablets are a highly effective combination therapy for advanced hormone-positive breast cancer. Choosing a trusted exporter is essential for quality and continuity of supply.
